Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 22:19:38 Source:politicsViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Tom Brady and Jay
Next:Independent UN experts urge Yemen’s Houthis to free detained Baha'i followers
You may also like
- Hollywood star Shia LaBeouf is spotted on the streets of Gavin and Stacey's hometown Barry
- Atlanta or Afghanistan? Wild shootout breaks out at gas station with one gunman wielding an AK
- Meghan Markle models 'love like a mother' t
- Emiliano Martinez is shown TWO yellow cards but little
- Flight attendant reveals why plane passengers should NEVER fall asleep before take off
- Gay 30 Rock actor Maulik Pancholy is canceled from anti
- US sanctions fundraisers for extremist West Bank settlers who commit violence against Palestinians
- Taylor Swift RELEASES The Tortured Poets Department! Grammy
- MPs' fury at 'virtue